Lyell Immunopharma (LYEL) EPS (Basic) (2020 - 2026)
Lyell Immunopharma (LYEL) reported EPS (Basic) of -$4.72 for Q1 2026, up 45.98% on a YoY basis from -$3.23 in Q1 2025, and up 44.26% sequentially from -$8.47 in Q4 2025.
Lyell Immunopharma (LYEL) EPS (Basic) (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of EPS (Basic) data on file, last reported at -$4.72 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Basic) rose 45.98% year-over-year to -$4.72; the trailing twelve-month figure through Mar 2026 stood at -$21.28 (up 66.73% YoY), and the FY2025 full-year result was -$16.76, up 69.47% from the prior year.
- EPS (Basic) rose to -$4.72 in Q1 2026, from -$8.47 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$4.72 in Q1 2026 to a low of -$42.91 in Q4 2024.
- A 5-year average of -$11.98 and a median of -$8.73 in 2025 frame the typical range for EPS (Basic).
- Across the five-year window, EPS (Basic) soared 99.99% in 2022 and slumped 75.51% in 2024, its largest moves.
- Tracing LYEL's EPS (Basic) over 5 years: stood at -$15.58 in 2022, then tumbled by 56.9% to -$24.45 in 2023, then tumbled by 75.51% to -$42.91 in 2024, then jumped by 80.27% to -$8.47 in 2025, then soared by 44.26% to -$4.72 in 2026.
- Business Quant data shows LYEL's EPS (Basic) at -$4.72 in Q1 2026, -$8.47 in Q4 2025, and -$5.59 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 0.00 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 0.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.16 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 4.06 |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 6.99 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 0.00 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 5.90 |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -2.29 |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -4.72 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.72 |
| Dec 31, 2025 | -8.47 |
| Sep 30, 2025 | -5.59 |
| Jun 30, 2025 | -7.81 |
| Mar 31, 2025 | -8.73 |
| Dec 31, 2024 | -42.91 |
| Sep 30, 2024 | -9.71 |
| Jun 30, 2024 | -10.14 |
| Mar 31, 2024 | -5.89 |
| Dec 31, 2023 | -24.45 |
| Sep 30, 2023 | -5.57 |
| Jun 30, 2023 | -7.26 |
| Mar 31, 2023 | -6.68 |
| Dec 31, 2022 | -15.58 |
| Sep 30, 2022 | -15.17 |
| Jun 30, 2022 | -10.55 |
| Mar 31, 2022 | -14.36 |
| Dec 31, 2021 | -25,944.97 |
| Sep 30, 2021 | -5,066.92 |
| Jun 30, 2021 | -81,415.73 |